{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:51:14Z","timestamp":1789001474340,"version":"build-2803163510"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T00:00:00Z","timestamp":1654214400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Current targeted pulmonary arterial hypertension (PAH) therapies have improved lung hemodynamics, cardiac function, and quality of life; however, none of these have reversed the ongoing remodeling of blood vessels. Considering notopterol, a linear furocoumarin extracted from the root of traditional Chinese medicine Qiang-Huo (<jats:italic>Notopterygium incisum<\/jats:italic>), had shown the antiproliferative and anti-inflammatory properties in previous studies, we hypothesized that it could play a role in ameliorating PAH.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p><jats:italic>In vivo<\/jats:italic>, we conducted monocrotaline (MCT) induced PAH rats and treated them with notopterol for 3 weeks. Then, the rats were examined by echocardiography and RV catheterization. The heart and lung specimens were harvested for the detection of gross examination, histological examination and expression of inflammatory molecules. <jats:italic>In vitro<\/jats:italic>, human pulmonary arterial smooth muscle cells (HPASMCs) were treated with notopterol after hypoxia; then, cell proliferation was assessed by cell counting kit-8 and Edu assay, and cell migration was detected by wound healing assays.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We found that notopterol improved mortality rate and RV function while reducing right ventricular systolic pressure in MCT-induced PAH rats. Furthermore, notopterol reduced right ventricular hypertrophy and fibrosis, and it also eased pulmonary vascular remodeling and MCT-induced muscularization. In addition, notopterol attenuated the pro-inflammatory factor (IL-1\u03b2, IL-6) and PCNA in the lungs of PAH rats. For the cultured HPASMCs subjected to hypoxia, we found that notopterol can inhibit the proliferation and migration of HPASMCs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our studies show that notopterol exerts anti-inflammatory and anti-proliferative effects in the pulmonary arteries, which may contribute to prevention of PAH.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcvm.2022.859422","type":"journal-article","created":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T05:15:06Z","timestamp":1654233306000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["Notopterol Attenuates Monocrotaline-Induced Pulmonary Arterial Hypertension in Rat"],"prefix":"10.3389","volume":"9","author":[{"given":"Lin","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huayang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suiqing","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunjun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuangjiao","family":"Gan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangguo","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"PeiYun","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangxian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongkai","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,6,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/nrcardio.2017.84","article-title":"Epidemiology and treatment of pulmonary arterial hypertension","volume":"14","author":"Lau","year":"2017","journal-title":"Nat Rev Cardiol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1146\/annurev-med-041717-085955","article-title":"New and emerging therapies for pulmonary arterial hypertension","volume":"70","author":"Spiekerkoetter","year":"2019","journal-title":"Annu Rev Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/S2213-2600(15)00542-1","article-title":"Treatment of pulmonary hypertension","volume":"4","author":"Hoeper","year":"2016","journal-title":"Lancet Respir Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"j5492","DOI":"10.1136\/bmj.j5492","article-title":"Pulmonary arterial hypertension: pathogenesis and clinical management","volume":"360","author":"Thenappan","year":"2018","journal-title":"BMJ."},{"key":"B5","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1177\/2040622315590757","article-title":"Medical treatment update on pulmonary arterial hypertension","volume":"6","author":"Enderby","year":"2015","journal-title":"Ther Adv Chronic Dis."},{"key":"B6","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1164\/rccm.201709-1835OC","article-title":"Endothelial and smooth muscle cell interaction via Foxm1 signaling mediates vascular remodeling and pulmonary hypertension","volume":"198","author":"Dai","year":"2018","journal-title":"Am J Respir Crit Care Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.ijcard.2016.06.192","article-title":"Thymoquinone attenuates monocrotaline-induced pulmonary artery hypertension via inhibiting pulmonary arterial remodeling in rats","volume":"221","author":"Zhu","year":"2016","journal-title":"Int J Cardiol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"105287","DOI":"10.1016\/j.phrs.2020.105287","article-title":"Resveratrol: mechanistic and therapeutic perspectives in pulmonary arterial hypertension","volume":"163","author":"Mirhadi","year":"2021","journal-title":"Pharmacol Res."},{"key":"B9","doi-asserted-by":"publisher","first-page":"4984","DOI":"10.3892\/mmr.2019.10781","article-title":"Formononetin attenuates monocrotalineinduced pulmonary arterial hypertension via inhibiting pulmonary vascular remodeling in rats","volume":"20","author":"Cai","year":"2019","journal-title":"Mol Med Rep."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1161\/CIRCULATIONAHA.113.004555","article-title":"Immune dysregulation and endothelial dysfunction in pulmonary arterial hypertension: a complex interplay","volume":"129","author":"Huertas","year":"2014","journal-title":"Circulation."},{"key":"B11","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/nrcardio.2011.87","article-title":"Mechanisms of disease: pulmonary arterial hypertension","volume":"8","author":"Schermuly","year":"2011","journal-title":"Nat Rev Cardiol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1055\/s-0029-1185971","article-title":"Antiproliferative and apoptotic activities of linear furocoumarins from Notopterygium incisum on cancer cell lines","volume":"76","author":"Wu","year":"2010","journal-title":"Planta Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.2147\/DDDT.S189969","article-title":"Notopterol-induced apoptosis and differentiation in human acute myeloid leukemia HL-60 cells","volume":"13","author":"Huang","year":"2019","journal-title":"Drug Des Devel Ther."},{"key":"B14","doi-asserted-by":"publisher","first-page":"108442","DOI":"10.1016\/j.celrep.2020.108442","article-title":"The natural compound notopterol binds and targets JAK2\/3 to ameliorate inflammation and arthritis","volume":"33","author":"Wang","year":"2020","journal-title":"Cell Rep."},{"key":"B15","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3109\/10408449209146311","article-title":"Mechanisms and pathology of monocrotaline pulmonary toxicity","volume":"22","author":"Wilson","year":"1992","journal-title":"Crit Rev Toxicol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"L784","DOI":"10.1152\/ajplung.00186.2018","article-title":"Galectin-3 is expressed in vascular smooth muscle cells and promotes pulmonary hypertension through changes in proliferation, apoptosis, and fibrosis","volume":"316","author":"Barman SA Li","year":"2019","journal-title":"Am J Physiol Lung Cell Mol Physiol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"eaba2470","DOI":"10.1126\/sciadv.aba2470","article-title":"DNA methyltransferase 3B deficiency unveils a new pathological mechanism of pulmonary hypertension","volume":"6","author":"Yan","year":"2020","journal-title":"Sci Adv"},{"key":"B18","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.bbrc.2020.01.015","article-title":"The SGLT2 inhibitor empagliflozin reduces mortality and prevents progression in experimental pulmonary hypertension","volume":"524","author":"Chowdhury","year":"2020","journal-title":"Biochem Bioph Res Commun."},{"key":"B19","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1164\/ajrccm-conference.2012.185.1_MeetingAbstracts.A6843","article-title":"Modern age pathology of pulmonary arterial hypertension","volume":"40","author":"Stacher","year":"2012","journal-title":"Eur Respir J"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e664836","DOI":"10.3389\/fphar.2021.664836","article-title":"Notopterol attenuates estrogen deficiency-induced osteoporosis via repressing RANKL signaling and reactive oxygen species","volume":"12","author":"Chen","year":"2021","journal-title":"Front Pharmacol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"e50","DOI":"10.1002\/ctm2.50","article-title":"A natural BACE1 and GSK3beta dual inhibitor notopterol effectively ameliorates the cognitive deficits in APP\/PS1 Alzheimer's mice by attenuating amyloid-beta and tau pathology","volume":"10","author":"Jiang","year":"2020","journal-title":"Clin Transl Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"111056","DOI":"10.1016\/j.biopha.2020.111056","article-title":"Protective effects of dioscin on vascular remodeling in pulmonary arterial hypertension via adjusting GRB2\/ERK\/PI3K-AKT signal","volume":"133","author":"Yang","year":"2021","journal-title":"Biomed Pharmacother."},{"key":"B23","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1161\/CIRCRESAHA.113.301141","article-title":"Inflammation and immunity in the pathogenesis of pulmonary arterial hypertension","volume":"115","author":"Rabinovitch","year":"2014","journal-title":"Circ Res."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1901761","DOI":"10.1183\/13993003.01761-2019","article-title":"Cellular sources of interleukin-6 and associations with clinical phenotypes and outcomes in pulmonary arterial hypertension","volume":"55","author":"Simpson","year":"2020","journal-title":"Eur Respir J"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1164\/ajrccm.151.5.7735624","article-title":"Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension","volume":"151","author":"Humbert","year":"1995","journal-title":"Am J Respir Crit Care Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1183\/09031936.00104706","article-title":"Fractalkine-induced smooth muscle cell proliferation in pulmonary hypertension","volume":"29","author":"Perros","year":"2007","journal-title":"Eur Respir J."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1802308","DOI":"10.1183\/13993003.02308-2018","article-title":"CCR2\/CCR5-mediated macrophage-smooth muscle cell crosstalk in pulmonary hypertension","volume":"54","author":"Abid","year":"2019","journal-title":"Eur Respir J"},{"key":"B28","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.omtn.2020.05.022","article-title":"Overexpression of MicroRNA-340-5p inhibits pulmonary arterial hypertension induced by APE by Downregulating IL-1beta and IL-6","volume":"21","author":"Ou","year":"2020","journal-title":"Mol Ther Nucleic Acids."},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.108.182014","article-title":"Interleukin-6 overexpression induces pulmonary hypertension","author":"Steiner","year":"2009","journal-title":"Circ Res"},{"key":"B30","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1465-9921-10-6","article-title":"Impact of interleukin-6 on hypoxia-induced pulmonary hypertension and lung inflammation in mice","volume":"10","author":"Savale","year":"2009","journal-title":"Respir Res"},{"key":"B31","doi-asserted-by":"publisher","first-page":"256","DOI":"10.2353\/ajpath.2008.070395","article-title":"Evidence of a role for osteoprotegerin in the pathogenesis of pulmonary arterial hypertension","volume":"172","author":"Lawrie","year":"2008","journal-title":"Am J Pathol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1183\/13993003.01448-2015","article-title":"Role of interleukin-1 receptor 1\/MyD88 signaling in the development and progression of pulmonary hypertension","volume":"48","author":"Parpaleix","year":"2016","journal-title":"Eur Respir J."},{"key":"B33","doi-asserted-by":"publisher","first-page":"e12742","DOI":"10.1111\/cpr.12742","article-title":"Blockade of JAK2 protects mice against hypoxia-induced pulmonary arterial hypertension by repressing pulmonary arterial smooth muscle cell proliferation","volume":"53","author":"Zhang","year":"2020","journal-title":"Cell Prolif."},{"key":"B34","doi-asserted-by":"publisher","first-page":"111081","DOI":"10.1016\/j.biopha.2020.111081","article-title":"Characteristics of inflammation process in monocrotaline-induced pulmonary arterial hypertension in rats","volume":"133","author":"Tang","year":"2021","journal-title":"Biomed Pharmacother."},{"key":"B35","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.3390\/ijms22042144","article-title":"mTOR signaling in pulmonary vascular disease: pathogenic role and therapeutic target","volume":"22","author":"Babicheva","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B36","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1093\/cvr\/cvt105","article-title":"Pathophysiological roles of nuclear factor kappaB. (NF-kB) in pulmonary arterial hypertension: effects of synthetic selective NF-kB inhibitor IMD-0354.","volume":"99","author":"Hosokawa","year":"2013","journal-title":"Cardiovasc Res"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1161\/HYPERTENSIONAHA.114.03220","article-title":"Inhibition of nuclear factor-kappaB in the lungs prevents monocrotaline-induced pulmonary hypertension in mice","volume":"63","author":"Li","year":"2014","journal-title":"Hypertension."},{"key":"B38","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/bs.apcsb.2016.11.006","article-title":"Targeting IKK and NF-kappaB for therapy","volume":"107","author":"Durand","year":"2017","journal-title":"Adv Protein Chem Struct Biol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/1476-4598-12-86","article-title":"The complexity of NF-kappaB signaling in inflammation and cancer","volume":"12","author":"Hoesel","year":"2013","journal-title":"Mol Cancer."},{"key":"B40","doi-asserted-by":"publisher","first-page":"4980","DOI":"10.3390\/ijms22094980","article-title":"The Role of JAK\/STAT molecular pathway in vascular remodeling associated with pulmonary hypertension","volume":"22","author":"Roger","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B41","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1165\/rcmb.2020-0384ED","article-title":"Inhibiting Jak2 ameliorates pulmonary hypertension: fulfilling the promise of precision medicine","volume":"64","author":"Leopold","year":"2021","journal-title":"Am J Respir Cell Mol Biol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1165\/rcmb.2019-0431OC","article-title":"Targeting jak-stat signaling in experimental pulmonary hypertension","volume":"64","author":"Yerabolu","year":"2021","journal-title":"Am J Respir Cell Mol Biol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1841527","DOI":"10.1155\/2020\/1841527","article-title":"Resveratrol prevents right ventricle remodeling and dysfunction in monocrotaline-induced pulmonary arterial hypertension with a limited improvement in the lung vasculature","volume":"2020","author":"Vazquez-Garza","year":"2020","journal-title":"Oxid Med Cell Longev."},{"key":"B44","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1161\/HYPERTENSIONAHA.120.14909","article-title":"Magnesium supplementation attenuates pulmonary hypertension via regulation of magnesium transporters","volume":"77","author":"Wang","year":"2021","journal-title":"Hypertension."},{"key":"B45","doi-asserted-by":"publisher","first-page":"5267","DOI":"10.7150\/thno.55571","article-title":"Cannabidiol attenuates pulmonary arterial hypertension by improving vascular smooth muscle cells mitochondrial function","volume":"11","author":"Lu","year":"2021","journal-title":"Theranostics."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.859422\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T05:15:10Z","timestamp":1654233310000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.859422\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,3]]},"references-count":45,"alternative-id":["10.3389\/fcvm.2022.859422"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2022.859422","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,3]]},"article-number":"859422"}}